ProMedica Toledo Hospital to study experimental stroke drug
ProMedica Toledo Hospital will conduct a multi-centered, randomized, Phase 3 research study to learn if the experimental drug recombinant Factor VIIa (rFVIIA), a protein that our body makes, can be used to decrease bleeding in the brain of patients who suffer sudden bleeding in the brain, also called intracerebral hemorrhage (ICH).